Rendimiento del HE4 en el diagnóstico, pronóstico y predicción de recidiva en cáncer de endometrio.

Autores:: Puentes Puentes, Luis Orlando
Amaya Pino, Juan Pablo

Tipo de recurso:: Article of journal

Fecha de publicación:: 2016

Institución:: Universidad de Cartagena

Repositorio:: Repositorio Universidad de Cartagena

Idioma:: spa

id	UCART2_3fbb5f61e4b1636ca8301b1f5fc67200
oai_identifier_str	oai:repositorio.unicartagena.edu.co:11227/13046
network_acronym_str	UCART2
network_name_str	Repositorio Universidad de Cartagena
repository_id_str
dc.title.spa.fl_str_mv	Rendimiento del HE4 en el diagnóstico, pronóstico y predicción de recidiva en cáncer de endometrio.
dc.title.translated.eng.fl_str_mv	HE4 performance in the diagnosis, prognosis and prediction of relapse in endometrial cancer.
title	Rendimiento del HE4 en el diagnóstico, pronóstico y predicción de recidiva en cáncer de endometrio.
spellingShingle	Rendimiento del HE4 en el diagnóstico, pronóstico y predicción de recidiva en cáncer de endometrio. Neoplasia endometrial Endometrio Biopsia Endometrial neoplasm Endometrium Biopsy
title_short	Rendimiento del HE4 en el diagnóstico, pronóstico y predicción de recidiva en cáncer de endometrio.
title_full	Rendimiento del HE4 en el diagnóstico, pronóstico y predicción de recidiva en cáncer de endometrio.
title_fullStr	Rendimiento del HE4 en el diagnóstico, pronóstico y predicción de recidiva en cáncer de endometrio.
title_full_unstemmed	Rendimiento del HE4 en el diagnóstico, pronóstico y predicción de recidiva en cáncer de endometrio.
title_sort	Rendimiento del HE4 en el diagnóstico, pronóstico y predicción de recidiva en cáncer de endometrio.
dc.creator.fl_str_mv	Puentes Puentes, Luis Orlando Amaya Pino, Juan Pablo
dc.contributor.author.spa.fl_str_mv	Puentes Puentes, Luis Orlando Amaya Pino, Juan Pablo
dc.subject.spa.fl_str_mv	Neoplasia endometrial Endometrio Biopsia
topic	Neoplasia endometrial Endometrio Biopsia Endometrial neoplasm Endometrium Biopsy
dc.subject.eng.fl_str_mv	Endometrial neoplasm Endometrium Biopsy
publishDate	2016
dc.date.accessioned.none.fl_str_mv	2016-07-15 00:00:00
dc.date.available.none.fl_str_mv	2016-07-15 00:00:00
dc.date.issued.none.fl_str_mv	2016-07-15
dc.type.spa.fl_str_mv	Artículo de revista
dc.type.coar.fl_str_mv	http://purl.org/coar/resource_type/c_2df8fbb1
dc.type.version.spa.fl_str_mv	info:eu-repo/semantics/publishedVersion
dc.type.coarversion.spa.fl_str_mv	http://purl.org/coar/version/c_970fb48d4fbd8a85
dc.type.coar.spa.fl_str_mv	http://purl.org/coar/resource_type/c_6501
dc.type.content.spa.fl_str_mv	Text
dc.type.driver.spa.fl_str_mv	info:eu-repo/semantics/article
dc.type.local.eng.fl_str_mv	Journal article
format	http://purl.org/coar/resource_type/c_6501
status_str	publishedVersion
dc.identifier.issn.none.fl_str_mv	2215-7840
dc.identifier.doi.none.fl_str_mv	10.32997/rcb-2016-2856
dc.identifier.eissn.none.fl_str_mv	2389-7252
dc.identifier.url.none.fl_str_mv	https://doi.org/10.32997/rcb-2016-2856
identifier_str_mv	2215-7840 10.32997/rcb-2016-2856 2389-7252
url	https://doi.org/10.32997/rcb-2016-2856
dc.language.iso.spa.fl_str_mv	spa
language	spa
dc.relation.ispartofjournal.spa.fl_str_mv	Revista Ciencias Biomédicas
dc.relation.bitstream.none.fl_str_mv	https://revistas.unicartagena.edu.co/index.php/cbiomedicas/article/download/2856/2399
dc.relation.citationedition.spa.fl_str_mv	Núm. 2 , Año 2016
dc.relation.citationendpage.none.fl_str_mv	284
dc.relation.citationissue.spa.fl_str_mv	2
dc.relation.citationstartpage.none.fl_str_mv	274
dc.relation.citationvolume.spa.fl_str_mv	7
dc.relation.references.spa.fl_str_mv	Bie Y, Zhang Z. Diagnostic value of serum HE4 in endometrial cancer: a meta-analysis. World J Surg Oncol. 2014; 12:169. https://doi.org/10.1186/1477-7819-12-169 NCCN. Clinical practice gidelines in oncology. Uterine Neoplasms version 2.2016 2016. World Health Organization, International Agency for Research on Cancer. Globocan 2012. Estimated cancer incidence, mortality and prevalence worldwide in 2012 [Internet]. Geneve: The Organization; 2015 [cited 2015/11/05]. Available from: http://globocan.iarc.fr/Default.aspx Pardo-Ramos C, Cendales-Duarte R. Incidencia, mortalidad y prevalencia de cáncer en Colombia, 2007-2011. Instituto Nacional de Cancerología. 2015. Burke WM, Orr J, Leitao M, Salom E, Gehrig P, Olawaiye AB, et al. Endometrial cancer: a review and current management strategies: part I. Gynecol Oncol. 2014; 134(2): 385-92. https://doi.org/10.1016/j.ygyno.2014.05.018 Pike MC, Peters RK, Cozen W, Probst-Hensch NM, Felix JC, Wan PC, et al. Estrogen-progestin replacement therapy and endometrial cancer. J Natl Cancer Inst. 1997; 89(15): 1110-6. https://doi.org/10.1093/jnci/89.15.1110 Fisher B, Costantino JP, Redmond CK, Fisher ER, Wickerham DL, Cronin WM. Endometrial cancer in tamoxifen-treated breast cancer patients: findings from the National Surgical Adjuvant Breast and Bowel Project (NSABP) B-14. J Natl Cancer Inst. 1994; 86(7): 527-37. https://doi.org/10.1093/jnci/86.7.527 Soliman PT, Wu D, Tortolero-Luna G, Schmeler KM, Slomovitz BM, Bray MS, et al. Association between adiponectin, insulin resistance, and endometrial cancer. Cancer. 2006; 106(11): 2376-81. https://doi.org/10.1002/cncr.21866 Soler M, Chatenoud L, Negri E, Parazzini F, Franceschi S, la Vecchia C. Hypertension and hormone-related neoplasms in women. Hypertension. 1999; 34(2): 320-5. https://doi.org/10.1161/01.HYP.34.2.320 McPherson CP, Sellers TA, Potter JD, Bostick RM, Folsom AR. Reproductive factors and risk of endometrial cancer. The Iowa Women's Health Study. Am J Epidemiol. 1996; 143(12): 1195-202. https://doi.org/10.1093/oxfordjournals.aje.a008707 Timmermans A, Opmeer BC, Khan KS, Bachmann LM, Epstein E, Clark TJ, et al. Endometrial thickness measurement for detecting endometrial cancer in women with postmenopausal bleeding: a systematic review and meta-analysis. Obstet Gynecol. 2010; 116(1): 160-7. https://doi.org/10.1097/AOG.0b013e3181e3e7e8 Epstein E, Ramirez A, Skoog L, Valentin L. Dilatation and curettage fails to detect most focal lesions in the uterine cavity in women with postmenopausal bleeding. Acta Obstet Gynecol Scand. 2001; 80(12): 1131-6. https://doi.org/10.1034/j.1600-0412.2001.801210.x Dijkhuizen FP, Mol BW, Brölmann HA, Heintz AP. The accuracy of endometrial sampling in the diagnosis of patients with endometrial carcinoma and hyperplasia: a meta-analysis. Cancer. 2000; 89(8): 1765-72. https://doi.org/10.1002/1097-0142(20001015)89:81765::AID-CNCR173.0.CO;2-F Connor JP, Andrews JI, Anderson B, Buller RE. Computed tomography in endometrial carcinoma. Obstet Gynecol. 2000; 95(5): 692-96. https://doi.org/10.1097/00006250-200005000-00012 Kitajima K, Murakami K, Yamasaki E, Kaji Y, Sugimura K. Accuracy of integrated FDG-PET/contrast-enhanced CT in detecting pelvic and paraaortic lymph node metastasis in patients with uterine cancer. Eur Radiol. 2009; 19(6): 1529-36. https://doi.org/10.1007/s00330-008-1271-8 Omer B, Genc S, Takmaz O, Dirican A, Kusku-Kiraz Z, Berkman S, et al. The diagnostic role of human epididymis protein 4 and serum amyloid-A in early-stage endometrial cancer patients. Tumour Biol. 2013; 34(5): 2645-50. https://doi.org/10.1007/s13277-013-0814-z Moore RG, Brown AK, Miller MC, Badgwell D, Lu Z, Allard WJ, et al. Utility of a novel serum tumor biomarker HE4 in patients with endometrioid adenocarcinoma of the uterus. Gynecol Oncol. 2008; 110(2): 196-201. https://doi.org/10.1016/j.ygyno.2008.04.002 Zanotti L, Bignotti E, Calza S, Bandiera E, Ruggeri G, Galli C, et al. Human epididymis protein 4 as a serum marker for diagnosis of endometrial carcinoma and prediction of clinical outcome. Clin Chem Lab Med. 2012; 50(12): 2189-98. https://doi.org/10.1515/cclm-2011-0757 Jiang SW, Chen H, Dowdy S, Fu A, Attewell J, Kalogera E, et al. HE4 transcription- and splice variants-specific expression in endometrial cancer and correlation with patient survival. Int J Mol Sci. 2013; 14(11): 22655-77. https://doi.org/10.3390/ijms141122655 Galgano MT, Hampton GM, Frierson HF. Comprehensive analysis of HE4 expression in normal and malignant human tissues. Mod Pathol. 2006; 19(6): 847-53. https://doi.org/10.1038/modpathol.3800612 Zhang AM, Zhang P. [Clinical value of combined detection of serum human epididymal secretory protein E4 and CA (125) in the diagnosis of endometrial carcinoma]. Zhonghua Fu Chan Ke Za Zhi. 2012; 47(2): 125-8. Angioli R, Plotti F, Capriglione S, Montera R, Damiani P, Ricciardi R, et al. The role of novel biomarker HE4 in endometrial cancer: a case control prospective study. Tumour Biol. 2013; 34(1): 571-6. https://doi.org/10.1007/s13277-012-0583-0 Bignotti E, Ragnoli M, Zanotti L, Calza S, Falchetti M, Lonardi S, et al. Diagnostic and prognostic impact of serum HE4 detection in endometrial carcinoma patients. Br J Cancer. 2011; 104(9): 1418-25. https://doi.org/10.1038/bjc.2011.109 Kemik P, Saatli B, Yıldırım N, Kemik VD, Deveci B, Terek MC, et al. Diagnostic and prognostic values of preoperative serum levels of YKL-40, HE-4 and DKK-3 in endometrial cancer. Gynecol Oncol. 2016; 140(1): 64-9. https://doi.org/10.1016/j.ygyno.2015.11.020 Kalogera E, Scholler N, Powless C, Weaver A, Drapkin R, Li J, et al. Correlation of serum HE4 with tumor size and myometrial invasion in endometrial cancer. Gynecol Oncol. 2012; 124(2): 270-5. https://doi.org/10.1016/j.ygyno.2011.10.025 Dobrzycka B, Mackowiak-Matejczyk B, Terlikowska KM, Kinalski M, Terlikowski SJ. Utility of HE4 to identify patients with endometrioid endometrial cancer who may require lymphadenectomy. Adv Med Sci. 2016; 61(1): 23-7. https://doi.org/10.1016/j.advms.2015.07.010 Mutz-Dehbalaie I, Egle D, Fessler S, Hubalek M, Fiegl H, Marth C, et al. HE4 is an independent prognostic marker in endometrial cancer patients. Gynecol Oncol. 2012; 126(2): 186-91. https://doi.org/10.1016/j.ygyno.2012.04.022 Saarelainen SK, Peltonen N, Lehtimäki T, Perheentupa A, Vuento MH, Mäenpää JU. Predictive value of serum human epididymis protein 4 and cancer antigen 125 concentrations in endometrial carcinoma. Am J Obstet Gynecol. 2013; 209(2): 142.e1-6. https://doi.org/10.1016/j.ajog.2013.04.014 Antonsen SL, Høgdall E, Christensen IJ, Lydolph M, Tabor A, Loft Jakobsen A, et al. HE4 and CA125 levels in the preoperative assessment of endometrial cancer patients: a prospective multicenter study (ENDOMET). Acta Obstet Gynecol Scand. 2013; 92(11): 1313-22. https://doi.org/10.1111/aogs.12235 Capriglione S, Plotti F, Miranda A, Ricciardi R, Scaletta G, Aloisi A, et al. Utility of tumor marker HE4 as prognostic factor in endometrial cancer: a single-center controlled study. Tumour Biol. 2015; 36(6): 4151-6. https://doi.org/10.1007/s13277-015-3049-3 Brennan DJ, Hackethal A, Metcalf AM, Coward J, Ferguson K, Oehler MK, et al. Serum HE4 as a prognostic marker in endometrial cancer a population based study. Gynecol Oncol. 2014; 132(1): 159-65. https://doi.org/10.1016/j.ygyno.2013.10.036 Moore RG, Miller CM, Brown AK, Robison K, Steinhoff M, Lambert-Messerlian G. Utility of tumor marker HE4 to predict depth of myometrial invasion in endometrioid adenocarcinoma of the uterus. Int J Gynecol Cancer. 2011; 21(7): 1185-90. https://doi.org/10.1097/IGC.0b013e3182229ad8 Minar L, Klabenesova I, Jandakova E, Zlamal F, Bienertova-Vasku J. Prognostic value of human epididymis protein 4 in endometrial cancer and its utility for surgical staging. J Obstet Gynaecol Res. 2015; 41(10): 1644-52. https://doi.org/10.1111/jog.12764 Benedetti Panici P, Basile S, Maneschi F, Alberto Lissoni A, Signorelli M, Scambia G, et al. Systematic pelvic lymphadenectomy vs. no lymphadenectomy in early-stage endometrial carcinoma: randomized clinical trial. J Natl Cancer Inst. 2008; 100(23): 1707-16. https://doi.org/10.1093/jnci/djn397 Kitchener H, Swart AM, Qian Q, Amos C, Parmar MK, group As. Efficacy of systematic pelvic lymphadenectomy in endometrial cancer (MRC ASTEC trial): a randomised study. Lancet. 2009; 373(9658): 125-36. https://doi.org/10.1016/S0140-6736(08)61766-3 Todo Y, Kato H, Kaneuchi M, Watari H, Takeda M, Sakuragi N. Survival effect of para-aortic lymphadenectomy in endometrial cancer (SEPAL study): a retrospective cohort analysis. Lancet. 2010; 375(9721): 1165-72. https://doi.org/10.1016/S0140-6736(09)62002-X Angioli R, Capriglione S, Scaletta G, Aloisi A, Miranda A, De Cicco Nardone C, et al. The role of HE4 in endometrial cancer recurrence: how to choose the optimal follow-up program. Tumour Biol. 2016; 37(4): 4973-78. https://doi.org/10.1007/s13277-015-4324-z Brennan DJ, Hackethal A, Mann KP, Mutz-Dehbalaie I, Fiegl H, Marth C, et al. Serum HE4 detects recurrent endometrial cancer in patients undergoing routine clinical surveillance. BMC Cancer. 2015; 15:33. https://doi.org/10.1186/s12885-015-1028-0
dc.rights.spa.fl_str_mv	Revista Ciencias Biomédicas - 2016
dc.rights.uri.spa.fl_str_mv	https://creativecommons.org/licenses/by-nc-sa/4.0/
dc.rights.coar.spa.fl_str_mv	http://purl.org/coar/access_right/c_abf2
dc.rights.accessrights.spa.fl_str_mv	info:eu-repo/semantics/openAccess
rights_invalid_str_mv	Revista Ciencias Biomédicas - 2016 https://creativecommons.org/licenses/by-nc-sa/4.0/ http://purl.org/coar/access_right/c_abf2
eu_rights_str_mv	openAccess
dc.format.mimetype.spa.fl_str_mv	application/pdf
dc.publisher.spa.fl_str_mv	Universidad de Cartagena
dc.source.spa.fl_str_mv	https://revistas.unicartagena.edu.co/index.php/cbiomedicas/article/view/2856
institution	Universidad de Cartagena
bitstream.url.fl_str_mv	https://repositorio.unicartagena.edu.co/bitstreams/870f757b-3ec1-4d90-91b1-1ec327cd92ac/download
bitstream.checksum.fl_str_mv	57260f6daa768728fe900aaba69e9e2b
bitstream.checksumAlgorithm.fl_str_mv	MD5
repository.name.fl_str_mv	Biblioteca Digital Universidad de Cartagena
repository.mail.fl_str_mv	bdigital@metabiblioteca.com
_version_	1814214239240323072
spelling	Puentes Puentes, Luis OrlandoAmaya Pino, Juan Pablo2016-07-15 00:00:002016-07-15 00:00:002016-07-152215-784010.32997/rcb-2016-28562389-7252https://doi.org/10.32997/rcb-2016-2856application/pdfspaUniversidad de CartagenaRevista Ciencias Biomédicashttps://revistas.unicartagena.edu.co/index.php/cbiomedicas/article/download/2856/2399Núm. 2 , Año 201628422747Bie Y, Zhang Z. Diagnostic value of serum HE4 in endometrial cancer: a meta-analysis. World J Surg Oncol. 2014; 12:169. https://doi.org/10.1186/1477-7819-12-169NCCN. Clinical practice gidelines in oncology. Uterine Neoplasms version 2.2016 2016.World Health Organization, International Agency for Research on Cancer. Globocan 2012. Estimated cancer incidence, mortality and prevalence worldwide in 2012 [Internet]. Geneve: The Organization; 2015 [cited 2015/11/05]. Available from: http://globocan.iarc.fr/Default.aspxPardo-Ramos C, Cendales-Duarte R. Incidencia, mortalidad y prevalencia de cáncer en Colombia, 2007-2011. Instituto Nacional de Cancerología. 2015.Burke WM, Orr J, Leitao M, Salom E, Gehrig P, Olawaiye AB, et al. Endometrial cancer: a review and current management strategies: part I. Gynecol Oncol. 2014; 134(2): 385-92. https://doi.org/10.1016/j.ygyno.2014.05.018Pike MC, Peters RK, Cozen W, Probst-Hensch NM, Felix JC, Wan PC, et al. Estrogen-progestin replacement therapy and endometrial cancer. J Natl Cancer Inst. 1997; 89(15): 1110-6. https://doi.org/10.1093/jnci/89.15.1110Fisher B, Costantino JP, Redmond CK, Fisher ER, Wickerham DL, Cronin WM. Endometrial cancer in tamoxifen-treated breast cancer patients: findings from the National Surgical Adjuvant Breast and Bowel Project (NSABP) B-14. J Natl Cancer Inst. 1994; 86(7): 527-37. https://doi.org/10.1093/jnci/86.7.527Soliman PT, Wu D, Tortolero-Luna G, Schmeler KM, Slomovitz BM, Bray MS, et al. Association between adiponectin, insulin resistance, and endometrial cancer. Cancer. 2006; 106(11): 2376-81. https://doi.org/10.1002/cncr.21866Soler M, Chatenoud L, Negri E, Parazzini F, Franceschi S, la Vecchia C. Hypertension and hormone-related neoplasms in women. Hypertension. 1999; 34(2): 320-5. https://doi.org/10.1161/01.HYP.34.2.320McPherson CP, Sellers TA, Potter JD, Bostick RM, Folsom AR. Reproductive factors and risk of endometrial cancer. The Iowa Women's Health Study. Am J Epidemiol. 1996; 143(12): 1195-202. https://doi.org/10.1093/oxfordjournals.aje.a008707Timmermans A, Opmeer BC, Khan KS, Bachmann LM, Epstein E, Clark TJ, et al. Endometrial thickness measurement for detecting endometrial cancer in women with postmenopausal bleeding: a systematic review and meta-analysis. Obstet Gynecol. 2010; 116(1): 160-7. https://doi.org/10.1097/AOG.0b013e3181e3e7e8Epstein E, Ramirez A, Skoog L, Valentin L. Dilatation and curettage fails to detect most focal lesions in the uterine cavity in women with postmenopausal bleeding. Acta Obstet Gynecol Scand. 2001; 80(12): 1131-6. https://doi.org/10.1034/j.1600-0412.2001.801210.xDijkhuizen FP, Mol BW, Brölmann HA, Heintz AP. The accuracy of endometrial sampling in the diagnosis of patients with endometrial carcinoma and hyperplasia: a meta-analysis. Cancer. 2000; 89(8): 1765-72. https://doi.org/10.1002/1097-0142(20001015)89:81765::AID-CNCR173.0.CO;2-FConnor JP, Andrews JI, Anderson B, Buller RE. Computed tomography in endometrial carcinoma. Obstet Gynecol. 2000; 95(5): 692-96. https://doi.org/10.1097/00006250-200005000-00012Kitajima K, Murakami K, Yamasaki E, Kaji Y, Sugimura K. Accuracy of integrated FDG-PET/contrast-enhanced CT in detecting pelvic and paraaortic lymph node metastasis in patients with uterine cancer. Eur Radiol. 2009; 19(6): 1529-36. https://doi.org/10.1007/s00330-008-1271-8Omer B, Genc S, Takmaz O, Dirican A, Kusku-Kiraz Z, Berkman S, et al. The diagnostic role of human epididymis protein 4 and serum amyloid-A in early-stage endometrial cancer patients. Tumour Biol. 2013; 34(5): 2645-50. https://doi.org/10.1007/s13277-013-0814-zMoore RG, Brown AK, Miller MC, Badgwell D, Lu Z, Allard WJ, et al. Utility of a novel serum tumor biomarker HE4 in patients with endometrioid adenocarcinoma of the uterus. Gynecol Oncol. 2008; 110(2): 196-201. https://doi.org/10.1016/j.ygyno.2008.04.002Zanotti L, Bignotti E, Calza S, Bandiera E, Ruggeri G, Galli C, et al. Human epididymis protein 4 as a serum marker for diagnosis of endometrial carcinoma and prediction of clinical outcome. Clin Chem Lab Med. 2012; 50(12): 2189-98. https://doi.org/10.1515/cclm-2011-0757Jiang SW, Chen H, Dowdy S, Fu A, Attewell J, Kalogera E, et al. HE4 transcription- and splice variants-specific expression in endometrial cancer and correlation with patient survival. Int J Mol Sci. 2013; 14(11): 22655-77. https://doi.org/10.3390/ijms141122655Galgano MT, Hampton GM, Frierson HF. Comprehensive analysis of HE4 expression in normal and malignant human tissues. Mod Pathol. 2006; 19(6): 847-53. https://doi.org/10.1038/modpathol.3800612Zhang AM, Zhang P. [Clinical value of combined detection of serum human epididymal secretory protein E4 and CA (125) in the diagnosis of endometrial carcinoma]. Zhonghua Fu Chan Ke Za Zhi. 2012; 47(2): 125-8.Angioli R, Plotti F, Capriglione S, Montera R, Damiani P, Ricciardi R, et al. The role of novel biomarker HE4 in endometrial cancer: a case control prospective study. Tumour Biol. 2013; 34(1): 571-6. https://doi.org/10.1007/s13277-012-0583-0Bignotti E, Ragnoli M, Zanotti L, Calza S, Falchetti M, Lonardi S, et al. Diagnostic and prognostic impact of serum HE4 detection in endometrial carcinoma patients. Br J Cancer. 2011; 104(9): 1418-25. https://doi.org/10.1038/bjc.2011.109Kemik P, Saatli B, Yıldırım N, Kemik VD, Deveci B, Terek MC, et al. Diagnostic and prognostic values of preoperative serum levels of YKL-40, HE-4 and DKK-3 in endometrial cancer. Gynecol Oncol. 2016; 140(1): 64-9. https://doi.org/10.1016/j.ygyno.2015.11.020Kalogera E, Scholler N, Powless C, Weaver A, Drapkin R, Li J, et al. Correlation of serum HE4 with tumor size and myometrial invasion in endometrial cancer. Gynecol Oncol. 2012; 124(2): 270-5. https://doi.org/10.1016/j.ygyno.2011.10.025Dobrzycka B, Mackowiak-Matejczyk B, Terlikowska KM, Kinalski M, Terlikowski SJ. Utility of HE4 to identify patients with endometrioid endometrial cancer who may require lymphadenectomy. Adv Med Sci. 2016; 61(1): 23-7. https://doi.org/10.1016/j.advms.2015.07.010Mutz-Dehbalaie I, Egle D, Fessler S, Hubalek M, Fiegl H, Marth C, et al. HE4 is an independent prognostic marker in endometrial cancer patients. Gynecol Oncol. 2012; 126(2): 186-91. https://doi.org/10.1016/j.ygyno.2012.04.022Saarelainen SK, Peltonen N, Lehtimäki T, Perheentupa A, Vuento MH, Mäenpää JU. Predictive value of serum human epididymis protein 4 and cancer antigen 125 concentrations in endometrial carcinoma. Am J Obstet Gynecol. 2013; 209(2): 142.e1-6. https://doi.org/10.1016/j.ajog.2013.04.014Antonsen SL, Høgdall E, Christensen IJ, Lydolph M, Tabor A, Loft Jakobsen A, et al. HE4 and CA125 levels in the preoperative assessment of endometrial cancer patients: a prospective multicenter study (ENDOMET). Acta Obstet Gynecol Scand. 2013; 92(11): 1313-22. https://doi.org/10.1111/aogs.12235Capriglione S, Plotti F, Miranda A, Ricciardi R, Scaletta G, Aloisi A, et al. Utility of tumor marker HE4 as prognostic factor in endometrial cancer: a single-center controlled study. Tumour Biol. 2015; 36(6): 4151-6. https://doi.org/10.1007/s13277-015-3049-3Brennan DJ, Hackethal A, Metcalf AM, Coward J, Ferguson K, Oehler MK, et al. Serum HE4 as a prognostic marker in endometrial cancer a population based study. Gynecol Oncol. 2014; 132(1): 159-65. https://doi.org/10.1016/j.ygyno.2013.10.036Moore RG, Miller CM, Brown AK, Robison K, Steinhoff M, Lambert-Messerlian G. Utility of tumor marker HE4 to predict depth of myometrial invasion in endometrioid adenocarcinoma of the uterus. Int J Gynecol Cancer. 2011; 21(7): 1185-90. https://doi.org/10.1097/IGC.0b013e3182229ad8Minar L, Klabenesova I, Jandakova E, Zlamal F, Bienertova-Vasku J. Prognostic value of human epididymis protein 4 in endometrial cancer and its utility for surgical staging. J Obstet Gynaecol Res. 2015; 41(10): 1644-52. https://doi.org/10.1111/jog.12764Benedetti Panici P, Basile S, Maneschi F, Alberto Lissoni A, Signorelli M, Scambia G, et al. Systematic pelvic lymphadenectomy vs. no lymphadenectomy in early-stage endometrial carcinoma: randomized clinical trial. J Natl Cancer Inst. 2008; 100(23): 1707-16. https://doi.org/10.1093/jnci/djn397Kitchener H, Swart AM, Qian Q, Amos C, Parmar MK, group As. Efficacy of systematic pelvic lymphadenectomy in endometrial cancer (MRC ASTEC trial): a randomised study. Lancet. 2009; 373(9658): 125-36. https://doi.org/10.1016/S0140-6736(08)61766-3Todo Y, Kato H, Kaneuchi M, Watari H, Takeda M, Sakuragi N. Survival effect of para-aortic lymphadenectomy in endometrial cancer (SEPAL study): a retrospective cohort analysis. Lancet. 2010; 375(9721): 1165-72. https://doi.org/10.1016/S0140-6736(09)62002-XAngioli R, Capriglione S, Scaletta G, Aloisi A, Miranda A, De Cicco Nardone C, et al. The role of HE4 in endometrial cancer recurrence: how to choose the optimal follow-up program. Tumour Biol. 2016; 37(4): 4973-78. https://doi.org/10.1007/s13277-015-4324-zBrennan DJ, Hackethal A, Mann KP, Mutz-Dehbalaie I, Fiegl H, Marth C, et al. Serum HE4 detects recurrent endometrial cancer in patients undergoing routine clinical surveillance. BMC Cancer. 2015; 15:33. https://doi.org/10.1186/s12885-015-1028-0Revista Ciencias Biomédicas - 2016https://creativecommons.org/licenses/by-nc-sa/4.0/http://purl.org/coar/access_right/c_abf2info:eu-repo/semantics/openAccessEsta obra está bajo una licencia internacional Creative Commons Atribución-NoComercial-CompartirIgual 4.0.https://revistas.unicartagena.edu.co/index.php/cbiomedicas/article/view/2856Neoplasia endometrialEndometrioBiopsiaEndometrial neoplasmEndometriumBiopsyRendimiento del HE4 en el diagnóstico, pronóstico y predicción de recidiva en cáncer de endometrio.HE4 performance in the diagnosis, prognosis and prediction of relapse in endometrial cancer.Artículo de revistainfo:eu-repo/semantics/publishedVersionhttp://purl.org/coar/version/c_970fb48d4fbd8a85http://purl.org/coar/resource_type/c_6501http://purl.org/coar/resource_type/c_2df8fbb1Textinfo:eu-repo/semantics/articleJournal articlePublicationOREORE.xmltext/xml2580https://repositorio.unicartagena.edu.co/bitstreams/870f757b-3ec1-4d90-91b1-1ec327cd92ac/download57260f6daa768728fe900aaba69e9e2bMD5111227/13046oai:repositorio.unicartagena.edu.co:11227/130462024-09-05 15:30:48.038https://creativecommons.org/licenses/by-nc-sa/4.0/Revista Ciencias Biomédicas - 2016metadata.onlyhttps://repositorio.unicartagena.edu.coBiblioteca Digital Universidad de Cartagenabdigital@metabiblioteca.com

Rendimiento del HE4 en el diagnóstico, pronóstico y predicción de recidiva en cáncer de endometrio.

Publicaciones similares